鸟苷酸环化酶(鸟苷酸环化酶,GC)可催化 GTP 形成 cGMP,存在于细胞的可溶部分和颗粒部分中。鸟苷酸环化酶通过产生第二信使 cGMP 发出信号。
GC 家族由颗粒 GC(pGC)和一氧化氮激活的可溶 GC(sGC)组成。目前已发现七种 pGC 同工酶(pGC-A 至 pGC-G)。pGC 通过将肽配体与其细胞外结构域结合而激活。sGC 是内源性和外源性一氧化氮的受体,结合后被激活数倍,构成一氧化氮信号转导途径中的核心酶。sGC 产生的 cGMP 是一种重要的第二信使,可调节多种酶的活性,从而引发血管舒张、平滑肌松弛和血小板聚集等重要生理反应。
Guanylate cyclase (guanylyl cyclase, GC), which catalyzes the formation of cGMP from GTP, exists in both the soluble and particulate fractions of cells. Guanylyl cyclases signal via the production of the second messenger cGMP.
The GC family consists of particulate GC (pGC) and a nitric oxide-activated soluble GC (sGC). Seven pGC isoforms have yet been found (pGC-A to pGC-G). pGCs are activated by binding of peptide ligands to their extracellular domains. sGC is a receptor for endogenous and exogenous nitric oxide and is activated several-fold upon its binding, constituting a core enzyme in the nitric oxide signal transduction pathway. cGMP generated by sGC is an important second messenger that regulates activity of several enzymes triggering such important physiologic reactions as vasodilation, smooth muscle relaxation and platelet aggregation.
Hsp110/sGC-modulator-1(compound 17i)是一种具有口服活性的 Hsp110/sGC 双靶点调节剂,兼具最佳的 Hsp110 与 sGC 分子活性以及显著的细胞恶性表型抑制和血管扩张作用,并通过抑制 Hsp110 减轻肺血管重构和右心室肥厚。
MCUF-651 是一种具有口服活性的鸟苷酸环化酶 A 受体 (GC-A) 正变构调节剂 (PAM)(KD: 397 nM),可与 GC-A 结合并选择性增强心房钠尿肽 (ANP) 与 GC-A 的结合,增强人心脏、肾和脂肪细胞中 ANP 介导的 cGMP 生成,并抑制心肌细胞肥大。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号